Malaria: Therapeutic implications of melatonin

Autores
Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; Brown, Gregory M.; Cardinali, Daniel Pedro
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.
Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; India
Fil: Spence, David Warren. Canadian Sleep Institute; Canadá
Fil: Moscovitch, Adam. Canadian Sleep Institute; Canadá
Fil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados Unidos
Fil: Trakht, Ilya. Columbia University; Estados Unidos
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
Apoptosis
Luzindole
Malaria
Melatonin Receptors
Oxidative Stress
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/53543

id CONICETDig_6d876b305f2f566e3d43f1fedbc5e015
oai_identifier_str oai:ri.conicet.gov.ar:11336/53543
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Malaria: Therapeutic implications of melatoninSrinivasan, VenkataramanujanSpence, David WarrenMoscovitch, AdamPandi Perumal, Seithikurippu R.Trakht, IlyaBrown, Gregory M.Cardinali, Daniel PedroApoptosisLuzindoleMalariaMelatonin ReceptorsOxidative Stresshttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; IndiaFil: Spence, David Warren. Canadian Sleep Institute; CanadáFil: Moscovitch, Adam. Canadian Sleep Institute; CanadáFil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados UnidosFil: Trakht, Ilya. Columbia University; Estados UnidosFil: Brown, Gregory M.. University of Toronto; CanadáFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaWiley Blackwell Publishing, Inc2010-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/53543Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-80742-3098CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/j.1600-079X.2009.00728.xinfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-079X.2009.00728.xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:23Zoai:ri.conicet.gov.ar:11336/53543instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:24.39CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Malaria: Therapeutic implications of melatonin
title Malaria: Therapeutic implications of melatonin
spellingShingle Malaria: Therapeutic implications of melatonin
Srinivasan, Venkataramanujan
Apoptosis
Luzindole
Malaria
Melatonin Receptors
Oxidative Stress
title_short Malaria: Therapeutic implications of melatonin
title_full Malaria: Therapeutic implications of melatonin
title_fullStr Malaria: Therapeutic implications of melatonin
title_full_unstemmed Malaria: Therapeutic implications of melatonin
title_sort Malaria: Therapeutic implications of melatonin
dc.creator.none.fl_str_mv Srinivasan, Venkataramanujan
Spence, David Warren
Moscovitch, Adam
Pandi Perumal, Seithikurippu R.
Trakht, Ilya
Brown, Gregory M.
Cardinali, Daniel Pedro
author Srinivasan, Venkataramanujan
author_facet Srinivasan, Venkataramanujan
Spence, David Warren
Moscovitch, Adam
Pandi Perumal, Seithikurippu R.
Trakht, Ilya
Brown, Gregory M.
Cardinali, Daniel Pedro
author_role author
author2 Spence, David Warren
Moscovitch, Adam
Pandi Perumal, Seithikurippu R.
Trakht, Ilya
Brown, Gregory M.
Cardinali, Daniel Pedro
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Apoptosis
Luzindole
Malaria
Melatonin Receptors
Oxidative Stress
topic Apoptosis
Luzindole
Malaria
Melatonin Receptors
Oxidative Stress
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.
Fil: Srinivasan, Venkataramanujan. Sri Sathya Sai Medical Educational And Research Foundation; India
Fil: Spence, David Warren. Canadian Sleep Institute; Canadá
Fil: Moscovitch, Adam. Canadian Sleep Institute; Canadá
Fil: Pandi Perumal, Seithikurippu R.. Somnogen Inc.; Estados Unidos
Fil: Trakht, Ilya. Columbia University; Estados Unidos
Fil: Brown, Gregory M.. University of Toronto; Canadá
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires"; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Malaria, which infects more than 300 million people annually, is a serious disease. Epidemiological surveys indicate that of those who are affected, malaria will claim the lives of more than one million individuals, mostly children. There is evidence that the synchronous maturation of Plasmodium falciparum, the parasite that causes a severe form of malaria in humans and Plasmodium chabaudi, responsible for rodent malaria, could be linked to circadian changes in melatonin concentration. In vitro melatonin stimulates the growth and development of P. falciparum through the activation of specific melatonin receptors coupled to phospholipase-C activation and the concomitant increase of intracellular Ca2+. The Ca2+ signaling pathway is important to stimulate parasite transition from the trophozoite to the schizont stage, the final stage of intraerythrocytic cycle, thus promoting the rise of parasitemia. Either pinealectomy or the administration of the melatonin receptor blocking agent luzindole desynchronizes the parasitic cell cycle. Therefore, the use of melatonin antagonists could be a novel therapeutic approach for controlling the disease. On the other hand, the complexity of melatonin's action in malaria is underscored by the demonstration that treatment with high doses of melatonin is actually beneficial for inhibiting apoptosis and liver damage resulting from the oxidative stress in malaria. The possibility that the coordinated administration of melatonin antagonists (to impair the melatonin signal that synchronizes P. falciparum) and of melatonin in doses high enough to decrease oxidative damage could be a novel approach in malaria treatment is discussed.
publishDate 2010
dc.date.none.fl_str_mv 2010-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/53543
Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-8
0742-3098
CONICET Digital
CONICET
url http://hdl.handle.net/11336/53543
identifier_str_mv Srinivasan, Venkataramanujan; Spence, David Warren; Moscovitch, Adam; Pandi Perumal, Seithikurippu R.; Trakht, Ilya; et al.; Malaria: Therapeutic implications of melatonin; Wiley Blackwell Publishing, Inc; Journal of Pineal Research; 48; 1; 1-2010; 1-8
0742-3098
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1600-079X.2009.00728.x
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-079X.2009.00728.x
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269635767959552
score 13.13397